Pharma Journalist -

Bioniz Therapeutics announced top-line results from its multiple ascending dose Phase 1b clinical trial of BNZ-1, a novel multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9,…
Read More...

THE FUTURE OF INJECTABLE DRUG DEVICES IS HERE! The highly anticipated 3-day conference will gather the growing injectable drugs community, filled with industry thought leaders and…
Read More...

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s…
Read More...

SMi Group reports: Pain Therapeutics conference is a one-stop shop to discover all of the cutting-edge news, updates and case-studies regarding developments in the field of analgesic…
Read More...

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by…
Read More...

AbbVie announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for risankizumab, an investigational interleukin-23 (IL-23)…
Read More...

Concert Pharmaceuticals announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The Company…
Read More...

Immune Therapeutics announced that the Kenya Pharmacy and Poison Board filed IMUN’s New Drug Application (NDA) for Lodonal, its lead drug candidate, thereby accepting the NDA for a full…
Read More...

Zoetis celebrated the start of construction on a combined global manufacturing and supply and research and development center in Suzhou, China, with a traditional groundbreaking…
Read More...

ADC Biotechnology (ADC Bio), announces that it has secured £1.14 million in funding from investment managers, Downing LLP. The funds will bolster the company’s business drive for faster…
Read More...